Sensei Biotherapeutics Inc (SNSE): Utang marang Ekuitas

Logo korporat perusahaan Sensei Biotherapeutics, Inc. (SNSE)

Targeted drug development at Sensei Biotherapeutics (SNSE) relies on high-tech biomaterial transport to ensure research precision. Simultaneously, the company is implementing ESG principles by reducing laboratory waste through digital modeling and protecting genetic information. Amid a shortage of monoclonal antibodies, the business possesses immense licensing potential. This price chart reflects that the total debt-to-equity ratio is 0.09.

SNSE: Rasio Total Utang marang Ekuitas Sensei Bio 04.07.2022 - 16.06.2026

Rincian metrik komprehensif lan analitis Sensei Biotherapeutics, Inc. (SNSE)

- rega lan prakiraan konsensus rega:
Bagan rega Sensei Biotherapeutics Inc|SNSE - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Sensei Biotherapeutics|SNSE - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Sensei Biotherapeutics|SNSE - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku senseibio.com|SNSE - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Sensei Biotherapeutics|SNSE - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Sensei Biotherapeutics Inc|SNSE - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Sensei Biotherapeutics|SNSE - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Sensei Biotherapeutics|Indikator likuiditas cepet senseibio.com
- informasi bathi lan kelipatan valuasi:
SNSE - Bathi pungkasan
Analisis fundamental perusahaan:Sensei Biotherapeutics, SNSE
Barang utama Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) maintains low sensitivity to external shocks due to the inelastic demand for oncology drugs and the success of the Immuno-Phage platform, which minimizes risks associated with the use of debt capital. Analyzing the total debt-to-equity ratio allows for an assessment of credit resources per unit of equity, helping investors determine the degree of financial leverage and the stability of the company's balance sheet.

Pesaing Sensei Biotherapeutics (SNSE)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|pyxisoncology.com (PYXS) - Rasio Utang marang Modal|Compugen - Rasio Total Utang marang Ekuitas|IO Biotech Inc. (IOBT) - Utang marang Modal|STRO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi INKT (minktherapeutics.com)|HOWL: Total Utang marang Modal|IMMX - Koefisien Total Utang marang Modal|Utang marang Ekuitas ALX Oncology Holdings|Rasio Total Utang marang Ekuitas cuebiopharma.com (CUE)|Utang marang Ekuitas PDS Biotechnology (PDSB)|Rasio Total Utang marang Ekuitas sonnetbio.com SONN|MAIA Biotechnology, Inc. - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Liminatus Pharma Inc. LIMN|LVTX - Utang marang Ekuitas|NXTC (NextCure Corporation) - Rasio Utang marang Ekuitas|leaptx.com (LPTX) - Utang marang Ekuitas|Utang marang Modal Intensity Therapeutics, Inc. (INTS)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal